Author: Niklas Mattsson

Patenting Antibody and Cell Therapies – What to Do and What Not to Do

Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great

Read more...

German Court finds Unified Patent Court legislation unconstitutional

Today, the court tasked with upholding Germany’s constitution, the Bundesverfassungsgericht, has issued its long-awaited decision on a complaint against

Read more...

UK is out of the Unified Patent Court

The United Kingdom’s government has confirmed to industry publication IAM-Media that the country will not be a member of

Read more...

German decision on UPC expected in early 2020

In an interview with IP industry publication Managing IP, Justice Huber of the German Federal Constitutional Court stated that

Read more...

Unitary SPCs in Europe after all?

As readers of this blog know, we at Awapatent are actively following the exciting developments in the creation of

Read more...

Myriad patent claims on breast cancer genes invalidated by US Supreme Court

In a decision on 13 June, the highest court of the USA, the US Supreme Court, said the final

Read more...

Breast cancer gene patents once again found valid by US appeals court

In the “Myriad case” an ongoing legal battle with many twists and turns, the Court of Appeals for the

Read more...

Focus on China

The fact that China is growing in importance is well known. To Awapatent, this growth is visible in our

Read more...

Supplementary protection for combination products heading for setback at the CJ of the EU

Supplementary protection for combination products heading for setback at the Court of Justice of the EU On 13 July

Read more...

Most comprehensive patent reform in almost 60 years approved by US senate

Most comprehensive patent reform in almost 60 years approved by US senate Historic breakthrough as USA gets to grips

Read more...

Mobile Sliding Menu